During the last forty years we have witnessed impressive advances in the field of antiviral
drug discovery culminating with the introduction of therapies able to stop human …

The recent outbreaks of avian influenza A (H5N1) virus, its expanding geographic
distribution and its ability to transfer to humans and cause severe infection have raised …

A ionization technique in mass spectrometry called Direct Analysis in Real Time Mass
Spectrometry (DART TOF-MS) coupled with a Direct Binding Assay was used to identify and …

Influenza is a long-standing health problem. For treatment of seasonal flu and possible
pandemic infections, there is a need to develop new anti-influenza drugs that have good …

The currently circulating H3N2 and H1N1 subtypes of influenza A virus cause a transient,
febrile upper respiratory illness in most adults and children (“seasonal influenza”), but …

Antiviral agents for the treatment of influenza are urgently needed to circumvent the
limitations of current drugs in several critical areas: high frequencies of resistance to M2 …

Influenza A viruses (IAVs) are zoonotic pathogens that cause yearly outbreaks with high
rates of morbidity and fatality. The virus continuously acquires point mutations while …

Two neuraminidase (NA) inhibitors, zanamivir (Relenza) and oseltamivir phosphate
(Tamiflu), have been licensed for the treatment of and prophylaxis against influenza. In this …

Covering: 2000 to 2011 The imminent threat of influenza pandemics and repeatedly
reported emergence of new drug-resistant influenza virus strains demonstrate the urgent …

Glycosidases are ubiquitous enzymes involved in a diversity of key biological processes
such as energy uptake or cell wall degradation. The design of specific glycosidase inhibitors …